SCHEMBL6040927

SCHEMBL6040927

C=CC(=O)c1c(C(=O)O)cccc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.54
FABP3 P05413 1/20 0.46
FABP4 P15090 1/20 0.46
FABP5 Q01469 1/20 0.46
BCAT2 O15382 1/20 0.44
AKT1 P31749 1/20 0.44
FOLH1 Q04609 2/20 0.43
ALDH1A1 P00352 3/20 0.42
ALOX15 P16050 1/20 0.42
MYC P01106 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTPN1 P18031 2/20 0.40
GPR52 Q9Y2T5 1/20 0.40
CHRNB2 P17787 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL229857 0.92 HNF4A (0.47) HNF4AFABP3FABP4FABP5BCAT2
SCHEMBL29376910 0.82 HNF4A (0.66) HNF4AFABP3FABP4FABP5BCAT2
SCHEMBL36146 0.82 HNF4A (0.66) HNF4AFABP3FABP4FABP5BCAT2
SCHEMBL2833055 0.80 HNF4A (0.63) HNF4AFABP3FABP4FABP5BCAT2
SCHEMBL6666734 0.80 HNF4A (0.63) HNF4AFABP3FABP4FABP5BCAT2
SCHEMBL5180034 0.80 BCAT2 (0.57) HNF4AFABP3FABP4FABP5BCAT2
Hydrochloric Acid SCHEMBL993304 0.80 HNF4A (0.63) HNF4AFABP3FABP4FABP5BCAT2
Bromide SCHEMBL8757513 0.80 HNF4A (0.63) HNF4AFABP3FABP4FABP5BCAT2
SCHEMBL31521259 0.80 BCAT2 (0.57) HNF4AFABP3FABP4FABP5BCAT2
Hydrochloric Acid SCHEMBL628183 0.80 HNF4A (0.63) HNF4AFABP3FABP4FABP5BCAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140275049-A1 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS ELI LILLY AND COMPANY 2014-09-18 US disclosed
US-20060189549-A1 Chalcone derivatives and their use to treat diseases NI LIMING 2006-08-24 US disclosed
US-7094801-B2 Chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2006-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189549-A1 Chalcone derivatives and their use to treat diseases CYP46A1, HSD17B7, CYP11B2 HNF4A 20/4885FABP3 955/4885FABP4 928/4885
US-20140275049-A1 SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS RARB, RARA, RARG HNF4A 209/4885FABP3 1617/4885FABP4 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.